Selected antimicrobial agents: Mechanisms of action, side effects and drug interactions

Periodontology 2000

Volumn 10, Issue 1, 1996, Pages 12-28

  Walker, Clay B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CELL WALL SKELETON; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; MACROLIDE; NITROIMIDAZOLE DERIVATIVE; NUCLEIC ACID SYNTHESIS INHIBITOR; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; RIFAMYCIN; TETRACYCLINE DERIVATIVE;

BIOSYNTHESIS; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG EFFECT; DRUG INTERACTION; HUMAN; REVIEW;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CELL MEMBRANE PERMEABILITY; CELL WALL SKELETON; CEPHALOSPORINS; CLINDAMYCIN; DRUG INTERACTIONS; HUMANS; MACROLIDES; NITROIMIDAZOLES; NUCLEIC ACID SYNTHESIS INHIBITORS; PENICILLINS; QUINOLONES; RIFAMYCINS; TETRACYCLINES;

EID: 0030072461     PISSN: 09066713     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0757.1996.tb00066.x     Document Type: Article

References (54)

1. Ciancio SG, Mather ML, McMullen JA. An evaluation of minocycline in patients with periodontal disease. J Periodontol 1980: 51: 530-534.
2. Fanning WL, Gump DW, Safferman RA. Side-effects of minocycline: a double-blind study. Antimicrob Agents Chemother 1977: 11: 712-717.
3. Fogdall RP, Miller RD. Prolongation of a pancuronium-induced neuromuscular blockage by clindamycin. Anesthesiology 1974: 41: 407-408.
4. Genco RJ. Using antimicrobial agents to manage periodontal diseases. J Am Dent Assoc 1991: 122: 31-38.
5. Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA. Pharamacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 1987: 31: 1948-1954.
6. Golub LM, Goodson JM, Lee HM, Vidal AM, McNamara TF, Ramamurthy NS. Tetracyclines inhibit tissue collagenases. J Periodontol 1985: 56(suppl.): 93-97.
7. Gordon J, Walker C, Holiaras C, Socransky S. Efficacy of clindamycin hydrochloride in refractory periodontitis: 24-month results. J Periodontol 1990: 61: 686-691.
8. Gordon J, Walker C, Lamster I, West T, Socransky S, Seiger M, Fasciano R. Efficacy of clindamycin hydrochloride in refractory periodontitis: 12-months results. J Periodontol 1985: 56(suppl): 75-80.
9. Gordon JM, Walker CB. Antibiotics in the treatment of periodontal disease: General concepts. J Periodontol 1993: 64(spec issue): 760-771.
10. Gordon JM, Walker CB, Goodson JM, Socransky SS. Sensitive assay for measuring tetracycline levels in gingival crevice fluid. Antimicrob Agents Chemother 1980: 17: 193-198.
11. Gordon JM, Walker CB, Murphy JC, Goodson JM, Socransky SS. Tetracycline levels achievable in gingival crevice fluid and in vitro effect on subgingival organisms. I. Concentrations in crevicular fluid after repeated doses. J Periodontol 1980: 52: 609-612.
12. Hesseltine HC, Lefebvre Y. Treating vaginal trichomoniasis with metronidazole. JAMA 1963: 184: 1011-1013.
13. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991: 91(suppl): 40S-45S.
14. Idsøe O, Guthe T, Willcox RR, DeWeck AL. Nature and extent of penicillin side reactions, with particular reference to fatalities from anaphylactic shock. Bull WHO 1968: 38: 159-188.
15. Jenkins WMM, MacFarlane TW, Gilmour WH, Ramsay I, MacKenzie D. Systemic metronidazole in the treatment of periodontitis. J Clin Periodontol 1989: 16: 443-450.
16. Levine BB. Antigenicity and cross reactivity of penicillins and cephalosporins. J Infect Dis 1973: 128: S364-S366.
17. Loesche WJ, Schmidt E, Smith BA, Morrison EC, Caffesso R, Hujoel P. Metronidazole in periodontitis. II. Effect upon treatment needs. J Periodontol 1991: 62: 247-257.
18. Loesche WJ, Syed SA, Morrison EC, Laughon B, Grossman MS. Treatment of periodontal infections due to anaerobic bacteria with short-term treatment with metronidazole. J Clin Periodontol 1981: 8: 29-44.
19. Mandell GL, Sande MA. Antimicrobial agents: penicillins, cephalosporins, and other beta-lactam antibiotics. In: Gilman AG, Rall TW, Nies AS, Taylor P, ed. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990.
20. Müller M. Mode of action of metronidazole on anaerobic microorganisms. In: Proc. U. S. Metronidazole Conf., 1982.
21. Neu HC. Penicillins. In: Mandell GL, Douglas RG, Bennett JE, ed. Principles and practices of infectious diseases. New York: John Wiley & Sons, 1985: 166-180.
22. Noble JI, Tally FP. Metronidazole. In: Ristuccia AM, Cunha BA, ed. Antimicrobial therapy. New York: Raven Press, 1984: 255-263.
23. Norris S, Mandell GL. The quinolones: history and overview. In: Andriole VT, ed. The quinolones. New York: Academic Press, 1988.
24. Pajukanta R. In vitro susceptibility of Porphyromonas gingivalis to azithromycin, a novel macrolide. Oral Microbiol Immunol 1993: 8: 325-326.
25. Pajukanta R, Asikainen S, Saarela M, Alaluusua S, Jousimies-Somer H. In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother 1992: 36: 1241-1243.
26. Parker CW. Drug allergy. N Engl J Med 1975: 292: 957-960.
27. Pascale D, Gordon J, Lamster I, Mann P, Seiger M, Arndt W. Concentrations of doxycycline in human gingival fluid. J Clin Periodontol 1986: 13: 841-844.
28. Piercy EA, Barbara D, Luby JP, Mackowiak PA. Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 1989: 33: 128-130.
29. Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1987: 31: 1939-1947.
30. Rifkin GD, Fekety FR, Silva J. Antibiotic-induced colitis: implication of a toxin neutralized by Clostridium sordellii antitoxin. Lancet 1977: 2: 1103-1106.
31. Roe FJC. Metronidazole: review of uses and toxicity. J Antimicrob Chemother 1977: 3: 205-212.
32. Sande MA, Mandell GL. Antimicrobial agents: tetracyclines, chloramphenicol, erythromycin, and miscellaneous antibacterial agents. In: Gilman AG, Rall TW, Nies AS, Taylor P, ed. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990: 1117-1145.
33. Sande MA, Mandell GL. Antimicrobial agents: The aminoglycosides. In: Gilman AG, Rall TW, Nies AS, Taylor P, ed. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990: 1098-1116.
34. Sanders CC. Ciprofloxacin: in vitro activity, mechanism of action, and resistance. Rev Infect Dis 1988: 10: 516-527.
35. Saxon A, Beau GN, Rohr AS, Adelman DC. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med 1987: 107: 204-215.
36. Schartz J, Jauregui L, Lettieri J, Bachmann K. Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum. Antimicrob Agents Chemother 1988: 32: 75-77.
37. Shinn DLS. Metronidazole in acute ulcerative gingivitis. Lancet 1962: 1: 1191.
38. Slots J, Rams TE. Antibiotics in periodontal therapy: advantages and disadvantages. J Clin Periodontol 1990: 17: 479-493.
39. Socransky SS. Effect of therapy on periodontal infections. J Periodontol 1993: 64: 754-759.
40. Somerman MJ, Foster RA, Vorsteg GM, Progebin K, Wynn RL. Effects of minocycline on fibroblast attachment and spreading. J Periodont Res 1988: 23: 154-159.
41. Tanner A. Microbial etiology of periodontal diseases: Where are we? Where are we going? Curr Opin Dent 1992: 2: 12-24.
42. Tedesco FJ. Clindamycin and colitis: a review. J Infect Dis 1977: 135S: 95-98.
43. Tomasz A, Holtje JV. Murine hydrolases and the lytic and killing action of penicillin. In: Schlessinger D, ed. Microbiology-1977. Washington, DC: Am Soc Microbiol, 1977: 209-215.
44. van Winkelhoff AJ, Rodenburg JP, Goene RJ, Abbas F, Winkel EG, de Graaff J. Metronidazole plus amoxicillin in the treatment of A. actinomycetemcomitans associated periodontitis. J Clin Periodontol 1989: 16: 128-131.
45. van Winkelhoff AJ, Tijhof CJ, de Graaff J. Microbiological and clinical results of metronidazole plus amoxicillin therapy in Actinobacillus actinomycetemcomitans associated periodontitis. J Periodontol 1992: 63: 52-57.
46. Walker C. Antimicrobial agents and chemotherapy. In: Slots J, Taubman MA, ed. Contemporary oral microbiology and immunology. St. Louis: Mosby Year Book, 1992: 242-264.
47. Walker CB, Gordon JM, Corwall HA, Murphy JC, Socransky SS. Gingival crevicular fluid levels of clindamycin compared with its minimal inhibitory concentration for periodontal bacteria. Antimicrob Agents Chemother 1981: 19: 867-871.
48. Walker CB, Gordon JM, Magnusson I, Clark WB. A role for antibiotics in the treatment of refractory periodontitis. J Periodontol 1993: 64(spec issue): 772-781.
49. Walker CB, Gordon JM, McQuilkin SJ, Niebloom TA, Socransky SS. Tetracycline: levels achievable in gingival crevice fluid and in vitro effect on subgingival organisms. II. Susceptibilities of periodontal bacteria. J Periodontol 1981: 52: 613-616.
50. Walker CB, Niebloom TA, Gordon JM, Socransky SS. In vitro susceptibilities of bacteria from human periodontal pockets to 13 antimicrobial agents. In: Nelson JD, Grassi C, ed. Current chemotherapy and infectious disease. Washington, DC: Am Soc Microbiol, 1980: 508-511.
51. Walker CB, Pappas JD, Tyler KZ, Cohen S, Gordon JM. Antibiotic susceptibilities of periodontal bacteria. In vitro susceptibilities to eight antimicrobial agents. J Periodontol 1985: 56(Suppl.): 67-74.
52. Weinstein AJ, Alanis A. Antibiotic side effects. In: Ristuccia AM, Cunha BA, ed. Antimicrobial therapy. New York: Raven Press, 1984: 339-363.
53. Weinstein L, Lerner PI, Chew WH. Clinical and bacteriologie studies on the effect of 'massive' doses of penicillin G on infections caused by gram-negative bacilli. N Engl J Med 1964: 271: 525-533.
54. Yocum RR, Waxman DW, Strominger JL. The mechanism of action of penicillin. J Biol Chem 1980: 255: 3977-3986.